Display options
Cite
Udupa SV, D'Souza V, Udupa VA, et al. Inherent suppression of thyroid stimulating hormone in newly diagnosed dyslipidemic patients - indication for use of thyromimetics?. J Clin Diagn Res. 2014;8(9):CC08-10doi: 10.7860/JCDR/2014/10363.4905.
Udupa, S. V., D'Souza, V., Udupa, V. A., & Manjrekar, P. A. (2014). Inherent suppression of thyroid stimulating hormone in newly diagnosed dyslipidemic patients - indication for use of thyromimetics?. Journal of clinical and diagnostic research : JCDR, 8(9), CC08-10. https://doi.org/10.7860/JCDR/2014/10363.4905
Udupa, Sridevi V, et al. "Inherent suppression of thyroid stimulating hormone in newly diagnosed dyslipidemic patients - indication for use of thyromimetics?." Journal of clinical and diagnostic research : JCDR vol. 8,9 (2014): CC08-10. doi: https://doi.org/10.7860/JCDR/2014/10363.4905
Udupa SV, D'Souza V, Udupa VA, Manjrekar PA. Inherent suppression of thyroid stimulating hormone in newly diagnosed dyslipidemic patients - indication for use of thyromimetics?. J Clin Diagn Res. 2014 Sep;8(9):CC08-10. doi: 10.7860/JCDR/2014/10363.4905. Epub 2014 Sep 20. PMID: 25386428; PMCID: PMC4225880.
Copy Download .nbib Format: NLM
Share it on

J Clin Diagn Res. 2014 Sep;8(9):CC08-10. doi: 10.7860/JCDR/2014/10363.4905. Epub 2014 Sep 20.

Inherent suppression of thyroid stimulating hormone in newly diagnosed dyslipidemic patients - indication for use of thyromimetics?.

Journal of clinical and diagnostic research : JCDR

Sridevi V Udupa, Vivian D'Souza, Vinit A Udupa, Poornima A Manjrekar

Affiliations

  1. Assistant Professor, Department of Biochemistry, Subbiah Institute of Medical Sciences , Shimoga, India .
  2. Professor, Department of Biochemistry, Centre for Basic sciences, Kasturba Medical College , Mangalore, India .
  3. Assistant Professor, Department of Pathology, Subbiah Institute of Medical Sciences , Shimoga, India .
  4. Professor and Head, Department of Biochemistry, Centre for Basic Sciences, Kasturba Medical College , Mangalore, India .

PMID: 25386428 PMCID: PMC4225880 DOI: 10.7860/JCDR/2014/10363.4905

Abstract

BACKGROUND: Dyslipidemia triggers a sequel of metabolic derangements such as insulin resistance, hyperglycemia and oxidative stress via vicious cycle. Dyslipidemia is characterised by elevation of plasma cholesterol, triglycerides (TGs), or both, or a low level of high-density lipoprotein (HDL) which in turn can progress to atherosclerosis a forerunner for ischemic heart disease (IHD). Dyslipidemia is seen even in subclinical hypothyroid patients.

OBJECTIVES: The aim of the study was to look for thyroid & glycemic abnormalities in dyslipidemic patients and compare it with euthyroid, normolipidemic group.

MATERIALS AND METHODS: Thirty primarily dyslipidemic patients and 30 euthyroid normolipidemic subjects aged 25-55 years were tested for fasting plasma glucose (FPG), fructosamine, lipid profile, thyroid hormones - T3, T4 and thyroid stimulating hormone (TSH). The values were compared with those of age matched euthyroid normolipidemic control group.

RESULTS: The dyslipidemic pool showed small but significant decrease in the TSH levels with comparable T3, T4 levels as compared to euthyroid group. The group also had significantly higher FPG, total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) levels and lower high density lipoprotein (HDL) levels as compared to the euthyroid normolipidemic group. The plasma fructosamine levels were similar in both the groups. The observed results reflected a picture of subclinical hyperthyroidism in dyslipidemic patients.

CONCLUSION: The observations of the present study preclude a need to assess the thyroid status in patients of primary dyslipidemia as both conditions per se have an increased risk of cardio vascular diseases. A subclinical hyperthyroid state may essentially be helpful in maintaining the lipid metabolism. The prevailing mild hyperthyroid status also makes it important to reconsider the accuracy of long term glycemic indicators like fructosamine and possibly glycated haemoglobin in these patients. Upon establishment of their efficacy and safety, thyromimetics may have a role in the treatment of dyslipidemia.

Keywords: Dyslipidemia; Fructosamine; Lipid profile; Subclinical hyperthyroidism

References

  1. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
  2. Circulation. 1986 Jan;73(1 Pt 2):I30-9 - PubMed
  3. J Clin Epidemiol. 2000 Jun;53(6):623-9 - PubMed
  4. J Clin Endocrinol Metab. 1997 Oct;82(10):3421-4 - PubMed
  5. Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):408-13 - PubMed
  6. Med Clin North Am. 2011 Sep;95(5):893-902 - PubMed
  7. Curr Atheroscler Rep. 2007 Nov;9(5):367-74 - PubMed
  8. Analyst. 1972 Feb;97(151):142-5 - PubMed
  9. J Clin Diagn Res. 2013 Jan;7(1):18-22 - PubMed
  10. Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S159-61 - PubMed
  11. Minerva Endocrinol. 1997 Dec;22(4):91-7 - PubMed
  12. Clin Endocrinol (Oxf). 2004 Oct;61(4):515-21 - PubMed
  13. J Am Vet Med Assoc. 1999 Nov 1;215(9):1297-300 - PubMed
  14. Open Cardiovasc Med J. 2011;5:76-84 - PubMed
  15. Clin Chem. 1974 Apr;20(4):470-5 - PubMed

Publication Types